Get started
Unicycive Therapeutics, Inc.Unicycive Therapeutics, Inc.Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Unicycive Therapeutics, Inc.



Key stats


Market capitalization
‪138.16 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.60 USD
Net income (FY)
‪−26.55 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪26.62 M‬
Beta (1Y)
1.07

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
21
Change (1Y)
−1−4.55%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.26 M‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Shalabh Gupta
Website
unicycive.com
Headquarters
Los Altos
Founded
2016
IPO date
Jul 13, 2021
ISIN
US90466Y2028
CUSIP
90466Y202
FIGI
BBG01163JG34
Identifiers
ISIN US90466Y2028
CFI code
ESVUFR
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral

Analyst rating


An aggregate view of professional's ratings.
Neutral
Neutral
Neutral

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWO
iShares Russell 2000 Growth Fund
Weight0.01%
Market value‪1.00 M‬
IWC
iShares Microcap ETF
Weight0.03%
Market value‪401.25 K‬
VTWG
Vanguard Russell 2000 Growth ETF
Weight0.01%
Market value‪121.37 K‬

Explore more ETFs 

Frequently asked questions


The current price of UNCY is 4.81 USD — it has decreased by −3.46% in the past 24 hours. Watch Unicycive Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unicycive Therapeutics, Inc. stocks are traded under the ticker UNCY.
UNCY stock has fallen by −1.27% compared to the previous week, the month change is a −15.10% fall, over the last year Unicycive Therapeutics, Inc. has showed a 21.46% increase.
We've gathered analysts' opinions on Unicycive Therapeutics, Inc. future price: according to them, UNCY price has a max estimate of 50.00 USD and a min estimate of 15.00 USD. Watch UNCY chart and read a more detailed Unicycive Therapeutics, Inc. stock forecast: see what analysts think of Unicycive Therapeutics, Inc. and suggest that you do with its stocks.
UNCY reached its all-time high on Jul 13, 2021 with the price of 87.30 USD, and its all-time low was 2.02 USD and was reached on Aug 13, 2024. View more price dynamics on UNCY chart.
See other stocks reaching their highest and lowest prices.
UNCY stock is 4.86% volatile and has beta coefficient of 1.07. Track Unicycive Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Unicycive Therapeutics, Inc. there?
Today Unicycive Therapeutics, Inc. has the market capitalization of ‪138.16 M‬, it has decreased by −6.80% over the last week.
Yes, you can track Unicycive Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Unicycive Therapeutics, Inc. is going to release the next earnings report on Nov 18, 2026. Keep track of upcoming events with our Earnings Calendar.
UNCY earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.47 USD resulting in a 87.26% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Unicycive Therapeutics, Inc. earnings.
Unicycive Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
UNCY net income for the last quarter is ‪−1.72 M‬ USD, while the quarter before that showed ‪−12.82 M‬ USD of net income which accounts for 0.00% change. Track more Unicycive Therapeutics, Inc. financial stats to get the full picture.
No, UNCY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 24, 2026, the company has 21 employees. See our rating of the largest employees — is Unicycive Therapeutics, Inc. on this list?
Like other stocks, UNCY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unicycive Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unicycive Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unicycive Therapeutics, Inc. stock shows the sell signal. See more of Unicycive Therapeutics, Inc. technicals for a more comprehensive analysis.